Q2 FY2027 · ended Jul 31, 2026 · Revenue $0 · Filed Sep 17, 2026
Vitaspring Biomedical Co., Ltd. (VSBC) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q2 of fiscal 2027, the quarter ended Jul 31, 2026, it reported revenue of $0 and a net loss of $155,817.
Revenue
$0
Net income
$-155,817
-40.6% vs year-ago quarter
Operating cash flow
$5,200
+538.4% vs year-ago quarter
Free cash flow
—
EPS
$0.00
Dividend per share
None
Shares outstanding
207.03M
+0.0% vs prior quarter
Net cash
$2,084
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- VSBC (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- NV
- Headquarters
- Riverside, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1697884
- Former names
- Shemn Corp. (until Apr 27, 2020)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2027 Jul 31, 2026 |
Q1 FY2027 Apr 30, 2026 |
Q4 FY2026 Jan 31, 2026 |
Q3 FY2026 Oct 31, 2025 |
Q2 FY2026 Jul 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating income | -$161,817 | -$75,844 | -$81,464 | -$135,733 | -$99,067 |
| Net income | -$155,817 | -$75,844 | -$81,464 | -$142,518 | -$110,845 |
| Diluted EPS | $0.00 | $0.00 | -$0.00 | $0.00 | $0.00 |
| Operating cash flow | $5,200 | $6,083 | $124 | -$839 | -$1,186 |
| Total assets | $14,822 | $11,432 | $14,676 | $16,465 | $17,020 |
| Total liabilities | $4.7M | $4.5M | $4.4M | $4.4M | $4.2M |
| Stockholders' equity | -$4.7M | -$4.5M | -$4.4M | -$4.3M | -$4.2M |
| Cash and investments | $13,367 | $8,167 | $2,084 | $1,960 | $799 |
| Total debt | — | — | $0 | $0 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Sep 17, 2026 | Jul 31, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 10, 2026 | Sep 7, 2026 |
| 10-K | Annual report | Jun 17, 2026 | Jan 31, 2026 |
| 10-Q | Quarterly report | Jun 17, 2026 | Apr 30, 2026 |
| 10-Q | Quarterly report | Jun 17, 2026 | Oct 31, 2025 |
| 10-Q | Quarterly report | Jun 17, 2026 | Jul 31, 2025 |
All 74 Vitaspring Biomedical Co., Ltd. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.